Fig. 1.

ROR1 expression and targeting in primary MCL patient samples, including CAR T-resistant MCL patient cells. (a) ROR1 expression detected by flow cytometry in primary MCL patient samples (n = 26), classified into four groups: BTKi-naïve (n = 4), BTKi-sensitive (n = 13), BTKi-resistant (n = 6) and CAR T-relapsed (n = 3). (b) Cell surface ROR1 expression of the four groups in (a) normalized to controls. (c) Dose-dependent inhibition of cell viability by MMAE-conjugated ROR1 antibody VLS-101. ROR1 targeting by VLS-101 is shown in a CAR T-relapsed MCL patient sample. Student t test was used to calculate statistical significance